April 22, 2025 06:16 AM EDTUpdated 06:36 AM

AstraZeneca, Daiichi eye first-line breast cancer market after Enhertu's early Phase 3 win

Elizabeth Cairns

Senior biopharma journalist

AstraZeneca and Daiichi Sankyo’s Enhertu cut the risk of progression or death compared with the standard of care for first-line HER2-positive metastatic breast cancer, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca, Daiichi eye first-line breast cancer market after Enhertu's early Phase 3 win

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

As the XBI suffers, Q1 shows a few comforting signs of underlying stability

Roche promises $50B investment in the US as pharma tariffs inch closer

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

As­traZeneca, Dai­ichi eye first-line breast can­cer mar­ket af­ter En­her­tu's ear­ly Phase 3 win

Senior biopharma journalist

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

AstraZeneca, Daiichi eye first-line breast cancer market after Enhertu's early Phase 3 win